1500P SOLARIS: A phase-II open-label Study of pembrOlizumab and Lenvatinib in patients with Advanced stage hepatocellular carcinoma who are Refractory to atezolizumab and bevacizumab/ IO-baSed therapy (IKF t-037 trial)
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.2130